Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

A new study focusing on the common CA-125 blood test found that some patients were 23 percent less likely to show elevated ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

One of the most exciting developments in ovarian cancer treatment in decades will form the basis of a new two-year research ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...

In a study on ovarian cancer cells, researchers from Karolinska Institutet demonstrate how the tumor environment influences ...

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

The cancer antigen (CA)-125 test may miss ovarian cancer in some Black and Native American patients, delaying their treatment ...